Multimodality risk adapted therapy with induction carboplatin/paclitaxel/lapatinib for SCCHN amenable to transoral surgery.

Jared Weiss,David N. Hayes,Allison M. Deal,Jose P. Zevallos,Bhishamjit S. Chera,Jennifer Paul,Mary Knowles,Dmitriy Usenko,Mark C. Weissler,S. Patel,Juneko E. Grilley-Olson,Trevor Hackman

Multimodality risk adapted therapy with induction carboplatin/paclitaxel/lapatinib for SCCHN amenable to transoral surgery.

2017

Jared Weiss
David N. Hayes
Allison M. Deal
Jose P. Zevallos
Bhishamjit S. Chera
Jennifer Paul
Mary Knowles
Dmitriy Usenko
Mark C. Weissler
S. Patel
Juneko E. Grilley-Olson
Trevor Hackman

6064Background: Induction chemotherapy in SCCHN has mostly been studied prior to XRT where proof of improved survival is lacking. Regimens using weekly platinum, taxane and targeted therapy have re...

Keywords:

Carboplatin/paclitaxel
Pathology
Oncology
Lapatinib
Medicine
Internal medicine
improved survival
transoral surgery
Taxane
Targeted therapy
Induction chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations